The epidemiology of multiple sclerosis (MS) is undergoing dramatic changes; MS is occurring with increased frequency in many parts of the world. In this retrospective study, we examined the changes in incidence and prevalence of MS in Kuwait in the period between 1993 and 2000. We analyzed the records of patients with clinically defined and laboratory supported MS. The total incidence rate increased from 1.05/100,000 population in 1993 to 2.62/100,000 in 2000. The increased incidence of MS was most pronounced among Kuwaiti women (from 2.26/100,000 in 1993 to 7.79/100,000 in 2000. The total prevalence rate increased from 6.68/100,000 in 1993 to 14.77/100,000 in 2000. It was much higher for Kuwaitis (31.15/100,000), as compared to non-Kuwaitis (5.55/ 100,000), in a complete reversal of the pattern observed before 1990. The prevalence was also higher among Kuwaiti women (35.54/100,000), as compared with Kuwaiti men (26.65/100,000). In conclusion, the incidence and prevalence of MS in Kuwait has increased between the early and late 1990s with no signs of leveling off. In a geographic area that was previously associated with low prevalence, local environmental factors may be responsible for these dramatic changes.

1.
Page WF, Kurtzke JF, Murphy FM, Norman JE Jr: Epidemiology of multiple sclerosis in US veterans. V. Ancestry and the risk of multiple sclerosis. Ann Neurol 1993;33:632–639.
2.
Al-Din AS, Khogali M, Poser CM: Epidemiology of multiple sclerosis in Arabs in Kuwait: A comparative study between Kuwaitis and Palestinians. J Neurol Sci 1990;100:137–141.
3.
Poser CM, Paty DW, Schienberg LC, McDonald W, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227–231.
4.
Patty DW, Oger JJF, Kastrukoff LF, et al: MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988;38:180–185.
5.
Ministry of Planning and Civil Information Authority: Kuwait Annual Census Report. Kuwait, Ministry of Planning and Civil Information Authority, 2001.
6.
Sahai H, Khurshid A: Statistics in Epidemiology: Methods, Techniques, and Applications. New York, CRC, 1995, p 169.
7.
EPI Info: Software for Epidemiology and Disease Surveillance, Version 6.02 Atlanta. Centers for Disease Control, Epidemiology Program Office, 1994.
8.
Wynn DR, Rodriguez M, O’Fallon WM, Kurland LT: A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990;40:780–786.
9.
Dean G, Bhigje AI, Bill OL, Fritz V, Chikanaza IC, Thomas JE, Levy Saffer D: Multiple sclerosis in back South Africans and Zimbabweans. J Neurol Neurosurg Psychiatry 1994;57:1064–1069.
10.
McLeod JG, Hammond SR, Hallpike JF: Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 1994;160:117–122.
11.
Pugliatti M, Sotgiu S, Rosati G: The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182–191.
12.
Rosati G: The prevalence of multiple sclerosis in the world: An update. Neurol Sci 2001;22:117–139.
13.
Warren S, Warren KG: Prevalence, incidence, and characteristics of multiple sclerosis in Westlock County, Alberta, Canada. Neurology 1993;43:1760–1763.
14.
Gonzalez O, Sotelo J: Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 1995;59:528–530.
15.
Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastru MI, Murgia B, Mannu L, Sanna G, Rosati G: Multiple sclerosis epidemiology in Sardinia: Evidence for a true increasing risk. Acta Neurol Scand 2001;103:20–26.
16.
Al-Din AS: Multiple sclerosis in Kuwait: A clinical and epidemiological study. J Neurol Neurosurg Psychiatry 1986;49:928–931.
17.
Poser C: The epidemiology of multiple sclerosis: A general overview. Ann Neurol 1994;36:S180–S193.
18.
Cook SD, Cromarty JI, Tap W, Poskanzer D, Walker JD, Dowling PC: Declining incidence of multiple sclerosis in the Orkney Islands. Neurology 1985;35:545–551.
19.
Marrie RA: Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 2004;3:709–718.
20.
Cooper GS, Miller FW, Germolec DR: Occupational exposures and autoimmune disease. Int Immunopharmacol 2002;2:303–313.
21.
Swank RL, Goodwin JW: How saturated fats may be a causative factor in multiple sclerosis and other diseases. Nutrition 2003;19:161–162.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.